A new option to ameliorate quality of life of advanced gallbladder carcinoma?

September 19, 2008,

GBC has very poor prognosis. Conventional surgery is considered the most effective treatment, but many cases are inoperable at the time of diagnosis. More recently, chemotherapy has shown activity in gallbladder cancer. However, no generally accepted standard chemotherapy for advanced, non-resectable cancer of the gallbladder or biliary tree has yet been established.

In addition, more and more people pay close attention to the research of Chinese medicine for prevention and treatment of cancer recently. Huachansu (cinobufagin) is just a widely used antitumor agent of traditional Chinese medicine in China. It is recommended that further clinical trials, especially large multi-institutional RCTs (phase III studies) using novel agents such as gemcitabine should be performed as soon as possible in order to establish a standard treatment.

A research article to be published on September, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Qin and Prof. Zhao from Department of Medical Oncology, First Affiliated Hospital of Medical School of Xi'an Jiaotong University, evaluated the efficacy and safety of GEMOX combined with huachansu in patients with advanced GBC, and assessed the patients' QOL.

In their study, patients with locally advanced or metastatic GBC were treated with gemcitabine 1000 mg/m2 intravenously over 30 minutes on d 1 and 8, oxaliplatin 120 mg/m2 as a 2-h infusion on d 1, and huachansu injection 20 mL/m2 (0.5 g/mL) as a 2 - 3 h infusion on d 3 through 11. Treatment was continued until unacceptable toxicity or disease progression. Quality of life was assessed by means of the EORTC QLQ-C30.

Out of the 23 patients whose response could be evaluated, 8 partial responses (PR) were observed (34.8%), while a further 7 patients (30.4%) demonstrated stable disease (SD). Disease control rate was 65.2%. In another 8 (34.8%) patients, the cancer progressed. The median progression-free survival and median overall survival were 5.8 mo and 10.5 mo, respectively.

The therapy was well tolerated, with moderate myelosuppression as the main toxicity. Non-hematologic toxicity ranged from mild to moderate. There were no toxic deaths.

"Huachansu injection was given three days before the GEMOX in our study and the effectiveness of huachansu in pain relief appeared 1 to 2 d after administration (9/14 patients)." Said Dr. Qin. "It showed an improvement for quality of life after the combination chemotherapy, and the scores of the QOL improved by 10 to 20 points."

The investigators believed that the GEMOX combined with huachansu injection provides a safe, well-tolerated, and effective treatment for patients with advanced GBC.

Source: World Journal of Gastroenterology

Related Stories

Recommended for you

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.